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Accepted 8 December 2020; Published online 28 December 2020AbstractObjective: Developing clinical prediction models (CPMs) on data of sufficient sample size is critical to help minimize overfitting. Us-
ing prostate cancer as a clinical exemplar, we aimed to investigate to what extent existing CPMs adhere to recent formal sample size
criteria, or historic rules of thumb of events per predictor parameter (EPP)  10.
Study Design and Setting: A systematic review to identify CPMs related to prostate cancer, which provided enough information to
calculate minimum sample size. We compared the reported sample size of each CPM against the traditional 10 EPP rule of thumb and
formal sample size criteria.
Results: About 211 CPMs were included. Three of the studies justified the sample size used, mostly using EPP rules of thumb. Overall,
69% of the CPMs were derived on sample sizes that surpassed the traditional EPP  10 rule of thumb, but only 48% surpassed recent formal
sample size criteria. For most CPMs, the required sample size based on formal criteria was higher than the sample sizes to surpass 10 EPP.
Conclusion: Few of the CPMs included in this study justified their sample size, with most justifications being based on EPP. This study
shows that, in real-world data sets, adhering to the classic EPP rules of thumb is insufficient to adhere to recent formal sample size
criteria.  2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Clinical prediction models (CPMs) are statistical models
or algorithms that can estimate the risk of existing disease
(diagnostic) or the probability of future outcomes (prog-
nostic) for an individual [1,2]. Estimations of risk are condi-
tional on the values of multiple predictors that are
observable at the time one wishes to make a prediction from
the model. Classically, these models are based on multivar-
iate modeling methods such as logistic regression for binary
outcomes or survival models for time-to-event outcomes.
Although there is a plethora of CPMs developed across
medical domains, very few are implemented clinically,
despite their many practical uses [1,3,4]. Commonly, thisFunding: None.
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licenses/by-nc-nd/4.0/).lack of uptake is attributed to reduced predictive perfor-
mance when CPMs are validated in independent cohorts
(e.g., external validation) [5e7]. Indeed, CPMs can suffer
from lack of generalizability, meaning that repeated de no-
vo development of CPMs is not uncommon [8]. The ways
in which CPMs are developed could also contribute to the
lack of uptake in practice.
Specifically, it is now recognized that the sample size
used to develop a CPM is crucial to help achieve robust pre-
dictive performance [9,10]. Small sample sizes may result
in extreme estimates of predictor effects (i.e., overfitting),
subsequently resulting in poor predictive performance
when applied to new patients. Although penalization and
shrinkage methods (such as LASSO or ridge regression)
are available to help with overfitting, these are not a solu-
tion to small sample size [11e13].
Historically, studies that develop CPMs have often justi-
fied their sample size based on events per predictor param-
eter (EPP)dthe ratio of the number of outcome events,cess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 This systematic review highlighted over 200 pre-
diction model published related to prostate cancer,
with very few of the included studies justifying
their choice of sample size; any justification were
usually being based on Events per Predictor
Parameter (EPP).
What this adds to what was known?
 The classic use of the EPP  10 rule of thumb is
not necessarily enough to guide sample size for
prediction model development based on formal
criteria.
 Our study highlights the extent to which this situa-
tion has previously been an issue, and so serves as
a benchmark for comparison in future reviews of
studies in the coming years
What is the implication and what should be done
now?
 There is large scope to improve the justification of
sample sizes used in prediction model studies and
single threshold values for EPP are insufficient to
do this accurately.
 Regardless of whether a sample size calculation
has been used, our recommendation is that the
justification for sample size consideration should
be included in all prediction model studies going
forward.
relative to the number of candidate predictor parametersd
with an EPP of  10 often taken as a rule of thumb
[14e16]. However, this blanket rule of thumb is too
simplistic [10,17,18]. As such, Riley et al. [11,19,20]
recently published a series of sample size formula to calcu-
late the minimum required sample size for binary, time to
event and continuous prediction models. Hereto, these sam-
ple size criteria will be referred to as ‘‘Riley et al.’’ with the
references being as follows: [11,19,20]. These criteria help
to ensure that the prediction model is robustly developed
[11]. Indeed, compared with previous guidance around
sample size requirements for prediction models, the Riley
et al. criteria are tailored to the model (and clinical context)
in question. For example, they are context-specific in terms
of outcome incidence and model fit. As such, in this study,
we take the Riley et al. criteria as the gold standard for sam-
ple size calculation.
However, it is unclear to what extent previously devel-
oped CPMs adhere to minimum required sample sizes as
calculated by the Riley et al. criteria. Therefore, the aim
54 S.D. Collins et al. / Journal of Clof this study was to use prostate cancer as a clinical exem-
plar in which to retrospectively assess whether published
multivariable CPMs adhere to the minimum sample size
criteria as outlined by Riley et al. [19,20] and the level of
agreement between these criteria and the EPP  10 rule
of thumb. We chose to focus on CPMs within prostate can-
cer because this is a common context in which CPMs are
developed in both a diagnostic and prognostic prediction
setting. This is largely due to their many practical uses,
including predicting disease onset [21]; risk stratification
[22]; predicting risk of upgrading during active surveillance
[23]; predicting risk of recurrence [24]; predicting risk of
treatment toxicity [25]; and predicting survival [26].2. Methods
We conducted and reported this systematic review as per
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [27].
2.1. Search strategy for the identification of studies
We undertook a literature search in Pubmed and Embase
using a published search filter specific to finding studies
related to CPMs [28]; this existing search filter was com-
bined with terms specific to prostate cancer (see
supplementary methods). We also searched the reference
list of any relevant systematic reviews that we discovered
in our database search to identify additional CPM develop-
ment studies for inclusion. The last search was conducted
on the June 30, 2019.
2.2. Eligibility criteria
We included any papers that developed a multivariable
model/score/tool/algorithm (hereto termed model) for pre-
dicting the individual risk of an outcome of interest in the
context of prostate cancer. Because we were interested in
models that output the risk of the outcome of interest, we
only included prediction models that were based on logistic
or cox regression for binary and time-to-event outcomes,
respectively [19]. To be included, the papers must have re-
ported sufficient information to allow us to retrospectively
calculate the Riley et al. minimum required sample size;
any study that did not report sufficient information was
excluded. We also excluded any papers that externally vali-
dated an existing model (without developing a new model)
and those that aimed to update an existing risk model with a
new predictor, although such papers were used to identify
the paper that developed the original CPM. Furthermore,
papers that developed CPMs for multiple anatomical sites
were excluded, as were those that were developed within
a competing risks/multistate modeling framework (because
multiple outcome regression is currently not covered by the
Riley et al. [19,20] criteria). Finally, we excluded any pa-
pers that were only available as an abstract (e.g., conference
55S.D. Collins et al. / Journal of Clinical Epidemiology 133 (2021) 53e60proceedings). We limited to papers published in English or
those available with an English translation. The study selec-
tion process was documented using the PRISMA flow dia-
gram [29], including reasons for exclusion.
2.3. Screening process
Initially, the titles and abstracts of identified papers were
screened by the lead author (S.D.C.), cross-referencing
against the inclusion and exclusion criteria. Papers satis-
fying the inclusion and exclusion criteria at this stage were
then full-text-screened (which further excluded papers as
required). Any uncertainty in whether to include/exclude
a particular study was resolved through discussion and
consensus with a second reviewer (G.P.M.).
2.4. Data extraction
Primary information that we extracted from identified
papers included the following: the sample size used (for
model development), the number of outcome events, the
predictor parameters considered, and the reported C-statis-
tic (to retrospectively calculate R2 as outlined by Riley
et al. [11,19,20]). In addition, for time-to-event models,
we extracted the mean follow-up and length of follow-up
reported in the papers. Extraction of all these values
enabled us to retrospectively calculate the Riley et al. min-
imum sample size criteria [19,20]. In addition, the EPP was
retrospectively calculated using the reported number of
events and number of predictors. For calculation of the
Riley et al. criteria and EPP, we considered the total de-
grees of freedom for all variables (of all candidate predic-
tors), where this was possible to determine; if the number
of candidate predictors was not reported, then the number
of parameters in the final model was used for the calcula-
tions. Finally, we noted if the study was reported in accor-
dance with the TRIPOD guidelines (transparent reporting
of a multivariable prediction model for individual prognosis
or diagnosis) [30], and whether the study conducted any
form of internal and/or external validation alongside the
model development.
2.5. Statistical analysis
Results were summarized using descriptive statistics.
We used logistic regression to examine if the odds of a pa-
per surpassing the EPP  10 rule of thumb or the Riley
et al. sample size criteria changed with time. We used the
chi-squared test to examine if the number of papers sur-
passing the EPP  10 rule of thumb and/or Riley et al. sam-
ple size criteria differed by study type (development/
internal/external validation) or clinical task (i.e., intended
prediction aim). All analyses were performed using R
version 3.6.2 [31], with the package ‘‘pmsampsize’’ [32]
used to calculate the Riley et al. required sample size.3. Results
The initial search identified 5,026 papers, with an addi-
tional 20 identified through citation searching of systematic
reviews (Supplementary Table 1); of these, 2,628 papers re-
mained following removal of duplicates. After the initial ti-
tle/abstract screening, 305 papers underwent full-text
screening, which identified 139 papers for inclusion. These
papers resulted in 211 CPMs (because some papers devel-
oped more than one CPM). Fig. 1 shows the PRISMA flow
diagram, and Supplementary Table 2 gives the full list of
included papers.
3.1. Study characteristics
The included papers were published between 1994 and
2019. The intended use of the CPM and the modeling
methods varied across the included studies (Table 1). Of
the 211 models included in this review, 124 (59%) focused
on diagnosis of prostate cancer, 9 (4%) on predicting side
effects, 44 (21%) on risk of progression/recurrence, and
34 (16%) on survival/mortality predictions. Overall, 143
CPMs were developed using logistic regression for binary
outcomes, and 68 using a Cox proportional hazards model
for time-to-event outcomes.
As shown in Table 1, 43 (20%) of the models detailed
development only, 116 (55%) also incorporated internal
validation (i.e., adjusted performance for in-sample opti-
mism) and 52 (25%) included development and external
validation (i.e., validation in an independent data set).
3.2. Adherence to sample size requirements: overall
From the 139 included studies, 34 (24%) acknowledged
limitations of the sample size used to develop their proposed
model(s), but only 3 studies outlined how they calculated
their minimum required sample size. Of these three studies,
the first used EPP  10 [33], the second used EPP  20
[34], and the third based their sample size calculation on
achieving ‘‘92% power [for] a noninferior sensitivity and su-
perior specificity’’ to a previously developed model [35].
Supplementary Table 2 depicts which of the included pa-
pers satisfied the traditional EPP  10 rule of thumb and
which satisfied the Riley et al. sample size criteria. Overall,
102 of the included CPMs (48%) were developed on sam-
ple sizes that surpassed the Riley et al. criteria, and 145
(69%) of the included models exceeded the traditional 10
EPP rule of thumb. Less than half of the models (47%)
satisfied both EPP  10 and the Riley et al. criteria
(Fig. 2), and 64 models failed to meet both criteria.
Across the CPMs that satisfied the Riley et al. sample
size criteria, there was large variability in their EPP
(Supplementary Fig. 1). In most CPMs, the Riley et al.
criteria resulted in a higher required sample size than that
based on EPP  10 (Fig. 3). About 38 (18%) of the
Fig. 1. Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) flow diagram.
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satisfy the Riley et al. criteria compared with the sample
size that would be required to surpass EPP  10. Here,
the calculated sample size from the Riley et al. formula
was driven by criteria 1 (small optimism in predictor effect
estimates) in 141 CPMs, criteria 2 (small difference in
apparent and adjusted model fit) in 5 CPMs and criteria 3
(precise estimation of overall risk) in 65 CPMs [11,19,20].
There was no evidence that the proportion of papers sur-
passing the Riley et al. sample size criteria changed through
time (P 5 0.323, Fig. 4). We found that study type (devel-
opment only/þinternal/þexternal validation) was signifi-
cantly associated with pass rate (P ! 0.001). Clinical
task was also associated with pass rate (P 5 0.005), sug-
gesting differing pass rates between diagnostic models, risk
of progression/recurrence models, side effects models, and
survival models.
3.3. Adherence to sample size requirements: binary
outcomes
Most of the included CPMs were developed for binary
outcomes (143 models), of which, 71% satisfied the  10EPP rule of thumb and 51% satisfied the Riley et al. sample
size criteria (Supplementary Table 2). Only 24 (17%)
models had a lower required minimum sample size to meet
the Riley et al. criteria compared with the sample size that
would be needed to meet the  10 EPP rule of thumb.
3.4. Adherence to sample size requirements: time-to-
event outcomes
Of the 68 included CPMs that were developed for time-
to-event outcomes, 65% satisfied the  10 EPP rule of
thumb, and 43% satisfied the Riley et al. criteria
(Supplementary Table 2). Only 14 (21%) of the time-to-
event CPMs had a lower required sample size according
to the Riley et al. criteria compared with the sample size
that would be required to surpass the  10 EPP rule of
thumb, again showing that the Riley et al. criteria are more
strict.
3.5. Quality assessment
Of all included studies, 46 were published after the pub-
lication of the TRIPOD guidelines [30], with only 4 (9%)
Table 1. Distribution of modeling techniques across prediction aim
Prediction aim Binary Time to event Total
All
Development 26 17 43
þ Internal validation 85 31 116
þ External validation 32 20 52
Total 143 68 211
Diagnosis
Development 20 1 21
þ Internal validation 74 1 75
þ External validation 27 1 28
Total 121 3 124
Side effects
Development 3 - 3
þ Internal validation 2 1 3
þ External validation 3 - 3
Total 8 1 9
Progression/recurrence
Development 3 8 11
þ Internal validation 7 16 23
þ External validation 2 8 10
Total 12 32 44
Survival/mortality
Development - 8 8
þ Internal validation 2 13 15
þ External validation - 11 11
Total 2 32 34
Note that 139 studies met the inclusion criteria, including 211
models.
Internal validation was defined as any appropriate method that was
used to adjust predictive performance for in-sample optimism, such
as bootstrap resampling. External validation was defined as any paper
that included an independent data set from a distinct population,
such as geographical validation.
Fig. 3. A scatter plot of the sample size that would be needed to
satisfy the events per predictor parameter (EPP)  10 rule of thumb
against the required sample size based on the Riley et al. criteria.
Both axes are on the log-scale to aid visual appearance of the plot.
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studies produced 6 CPMs, of which only 1 satisfied both
the traditional rule of thumb and Riley et al. criteria [37],
and all six were based on cox proportional hazards models.Fig. 2. A Venn diagram of the included models which surpass and fail
to meet events per predictor parameter (EPP)  10 and the Riley et al.
criteria. A total of 64 models failed to meet both criteria.4. Discussion
This systematic review adds important implications to
the literature. First, it shows that sample sizes are rarely
justified in this field. Second, it highlights that the classic
use of EPP10 is not necessarily sufficient to guide sample
size for prediction model development based on formal
criteria. Thirdly, regardless of whether a sample size calcu-
lation has been used, our recommendation is that a justifi-
cation for sample size should be included in all
prediction model studies going forward (as a minimum).
Finally, our study highlights the extent to which this situa-
tion has previously been an issue, and so serves as a bench-
mark for comparison in future reviews of studies in the
coming years (that should aim to examine if improvements
have been made). To be clear, the intention of this paper is
not to point blame at previous studies in terms of sample
size and justification of sample size, but rather highlight
to readers that this topic is an important and outstanding
issue in the reporting of prediction model studies.
This study found over 200 published CPMs for risk pre-
diction in prostate cancer, but only three justified the sam-
ple size used, most of which were based on EPP rules of
thumb. We were not able to determine the precise reasons
why studies might not justify sample size. One potential
reason is that some studies included in this review were
published before the TRIPOD guidelines (which includes
an item to report how the sample size was arrived at). In
addition, we postulate that this also reflects the historic lack
of formal guidelines around required sample size in CPM
development studies, and the historic blanket use of EPP
rules of thumb [14e16]. Indeed, several systematic reviews
have observed that prediction model studiesdboth devel-
opment and validationefrequently provide no rationale
for the sample size used, or discuss the potential for over-
fitting [3,40,41]. The recently published Riley et al. criteria
[19,20] provide the required mechanism to allow sample
size justification. It is also possible that if researchers have
access to a data set of fixed sample size, then sample size
Fig. 4. The number of clinical prediction models (CPMs) related to prostate cancer that have been published, and the number of those that satisfy
the Riley et al. sample size criteria.
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criteria should be used to determine the maximum number
of candidate predictor variables for the fixed sample size.
We acknowledge that all of the CPMs considered in this
review were published before the Riley et al. sample size
criteria [19,20] (which were published in 2019); conse-
quently, one cannot expect historically derived CPMs to
adhere to these criteria (and, again, we do not intend to
point blame). Nonetheless, our findings highlight the
importance of carefully justifying the required sample size
in all future CPM development studies. The TRIPOD
guidelines include the requirement to report how the study
sample size was obtained [30]; our findings suggest that
these guidelines should be extended to include a require-
ment for papers to formally justify the sample size (e.g., us-
ing the Riley et al. criteria). To use the Riley et al. criteria
in practice, one needs to specify the anticipated model fit
(i.e., R2) in advance of data collection/model fitting
[11,19,20]. In this study, we based the sample size calcula-
tion on the performance of the fitted model; thus, it could
be thatdin the futuredmodelers adhere to the Riley
et al. guidance but are too optimistic in the value of R2 that
they choose. In such a case, it would retrospectively appear
that the study failed to meet the criteria. Therefore, we sug-
gest that all steps of the Riley et al. calculation should be
reported in development papers.
Importantly, we found that only 48% of included CPMs
surpassed the Riley et al. sample size criteria [19,20],
whereas 68% had an EPP  10. It is now widely accepted
that an EPP 10 is overly simplistic [42e45]. Indeed, this
study found that there was large spread in the EPP for
studies that satisfied the Riley et al. criteria
(Supplementary Fig. 1), demonstrating that a single
threshold value for EPP is insufficient; this supportsexisting research in this area [10,17,18]. In addition, in
most cases, the Riley et al. sample size formula
[11,19,20] resulted in higher sample sizes than the sample
sizes that would be needed to meet an EPP  10, with
the former usually being based on minimizing overfitting
(i.e., criteria 1 of Riley et al. [11,19,20]). In other words,
if a particular study met the 10 EPP rule of thumb, then this
does not guarantee that it is likely to meet the Riley criteria,
which is often more stringent. This finding reinforces that
EPP is not suitable to guide sample size for CPM
development.
In addition, we found that studies including internal/
external validation alongside model development had high-
er odds of surpassing the Riley et al. criteria, compared
with studies that only included CPM derivation. This
finding suggests that sample size improvements are linked
to having improved methodology in general within CPM
studies. Furthermore, it is currently unknown if adhering
to formal sample size criteria leads to greater generaliz-
ability of predictive performance [1,3,4]. Lack of generaliz-
ability of CPMs might lead to individual institutes/centers/
research groups developing de novo models on local data,
and this could further compound the issues with low sample
size. Indeed, lack of sufficient sample size in local settings
increases the risk of overfitting. Further research is required
to explore both of these points in more detail.
Similarly, further research is needed around sample size
requirements for modeling methods such as ordinal, multi-
nomial, competing risks/multistate models and machine
learning methods. Indeed, while the sample size criteria
outlined by Riley et al. [19,20] provides guidance for logis-
tic, cox, and linear regression models, this study identified
other modeling techniques being used to develop CPMs in
prostate cancer, which we excluded due to the lack of
59S.D. Collins et al. / Journal of Clinical Epidemiology 133 (2021) 53e60sample size formula. For example, owing to the rise in
popularity of machine learning techniques, guidance
around sample size has become more pertinent [46], espe-
cially because they are often ‘‘data hungry’’ [47].
Several limitations should be considered when interpret-
ing the results of this study. First, the search was completed
until June 2019. Prompted by a reviewer comment, we
examined a random sample of 10 articles published be-
tween June 2019 and November 2020 (time of the first
reviewer comments) and we found very similar conclu-
sions; for example, 53% surpassed the Riley sample size
criteria, which is similar to the 48% in the main paper. Sec-
ond, this analysis was retrospective, meaning that most of
the included studies were published before the publication
of the Riley et al. sample size criteria. Future work should
explore if adherence increases in the future. Third, 37
studies were excluded due to insufficient information being
reported to calculate the Riley et al. sample size criteria.
Such exclusion potentially introduces bias into our findings
if such papers differ from those included in terms of their
reported sample size relative to the required sample size.
Fourth, this review focused on prediction models in the
prostate cancer domain; such a domain-specific focus was
required because of the large number of CPMs that are pub-
lished across medical domains. As such, one could argue
that the findings might not generalize to other clinical areas.
In conclusion, historically few CPM development studies
have justified their choice of sample size, with any justifica-
tion usually being based on EPP. This systematic review has
highlighted that the classic EPP  10 rule of thumb is not
necessarily sufficient to guide sample size for CPM develop-
ment, even though it is the most used metric. The findings
also show that there is a need to drastically improve the justi-
fication of sample sizes used in prediction model studies;
justification for how the sample size was arrived at should
be the bare minimum regardless of how data were collected
(e.g., by conducting a new cohort study, or by using an ex-
isting data set already available). The Riley et al. criteria
now provide the required means of doing this in the future.
Although a historic lack of justification is perhaps unsurpris-
ing (given that the Riley et al. criteria have only recently
been published), future work should monitor whether this
situation improves in the future.Acknowledgments
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